Part,  Chapter, Paragraph

 1   II,     5.  1.  1|                                 accumulation endogenous inhibitors of nitric oxide synthase
 2   II,     5.  2.  5|                           angiotensin-converting-enzyme inhibitors; statins etc) explain less
 3   II,     5.  2.  6|                           angiotensin-converting-enzyme inhibitors; statins etc) explain less
 4   II,     5.  7.  4|                                 accumulation endogenous inhibitors of nitric oxide synthase (
 5   II,     5.  8.  6|                           selective phosphodiesterase 4 inhibitors are in the late phases of
 6   II,     9        | hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), and angiotensin-converting
 7   II,     9        |                     angiotensin-converting enzyme (ACE) inhibitors reduce risk for CHD events
 8   II,     9        |                 hypercholesterolemia, HMG-CoA reductase inhibitors (statins) reduce risk for
 9   II,     9.  3.  1| hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), and angiotensin-converting
10   II,     9.  3.  1|                     angiotensin-converting enzyme (ACE) inhibitors reduce risk for CHD events
11   II,     9.  3.  1|                 hypercholesterolemia, HMG-CoA reductase inhibitors (statins) reduce risk for
12  III,    10.  4.  2|                     dicarboxyamides, phalimide, spindle inhibitors, and dithiocarbamates. Whilst